Masitinib Plus Gemcitabine in Pancreatic Cancer
Lykilorð
Útdráttur
Lýsing
Masitinib is a selective tyrosine kinase inhibitor that is thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment. The objective of this study is to evaluate the efficacy and safety of masitinib in combination with gemcitabine with respect to placebo in combination with gemcitabine for the treatment of non resectable locally advanced or metastatic pancreatic cancer patients with pain related to the disease. Approximately 330 patients with pain Visual Analogue Scale (VAS) > 20 and/or treated with 'opioid analgesics' dose ≥ 1 mg/kg/day at baseline will be randomized in a 2:1 ratio to the masitinib and placebo arms, respectively. The primary outcome measure is overall survival (OS).
Dagsetningar
| Síðast staðfest: | 03/31/2020 |
| Fyrst lagt fram: | 12/03/2018 |
| Áætluð skráning lögð fram: | 12/03/2018 |
| Fyrst sent: | 12/05/2018 |
| Síðasta uppfærsla lögð fram: | 04/02/2020 |
| Síðasta uppfærsla sett upp: | 04/05/2020 |
| Raunverulegur upphafsdagur náms: | 06/30/2014 |
| Áætlaður aðallokunardagur: | 08/31/2020 |
| Áætlaður dagsetningu rannsóknar: | 08/31/2020 |
Ástand eða sjúkdómur
Íhlutun / meðferð
Drug: Masitinib & gemcitabine
Drug: Gemcitabine
Drug: Placebo & gemcitabine
Stig
Armhópar
| Armur | Íhlutun / meðferð |
|---|---|
| Experimental: Masitinib & gemcitabine Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal. | Drug: Masitinib & gemcitabine |
| Active Comparator: Placebo & gemcitabine Participants receive matching placebo, given orally twice daily, plus gemcitabine at 1000mg/m2 by intravenous infusion during 30 minutes, once every 7 days, for up to 7 weeks, followed by a week of rest. Subsequent cycles should consist of an IV infusion, once every 7 days, for 3 consecutive weeks out of every 4 weeks, until disease progression, death, limiting toxicity or patient consent withdrawal. | Drug: Placebo & gemcitabine |
Hæfniskröfur
| Aldur hæfur til náms | 18 Years Til 18 Years |
| Kyn sem eru hæf til náms | All |
| Tekur við heilbrigðum sjálfboðaliðum | Já |
| Viðmið | Main inclusion criteria: 1. Histologically or cytologically confirmed adenocarcinoma of the pancreas, non resectable locally advanced or metastatic stage 2. Patient with pain related to the disease, as assessed by the investigator and the patient: - Pain related to the disease as assessed by the investigator is defined as clinical and documented evaluation by the investigator during physical examinations at screening and/or baseline. - Pain, as assessed by the patient is defined as at least one value out of two values > 20mm on Visual Analogue Scale at screening or baseline. Visual Analogic scale consists in the visual representation of pain amplitude as perceived by the patient. The amplitude is represented by a 100 mm long line having no reference marks. One extremity indicates an absence of pain (0 value) and the other the worst imaginable pain (100 value). OR - Patient treated with opioid analgesics at a dose ≥ 1 mg/kg/day (morphinic equivalent). 3. Chemotherapy naïve patient for the advanced/metastatic disease Main exclusion criteria: 1. Patient with no pain related to the disease (as defined in the inclusion criterion number 2) 2. Pregnant or nursing female patient |
Útkoma
Aðal niðurstöður ráðstafanir
1. Overall Survival (median) [From day of randomization to death, assessed for a maximum of 60 months]
Aðgerðir vegna aukaatriða
1. Survival rates [every 24 weeks]
2. Progression Free Survival [From day of randomization to disease progression or death, assessed for a maximum of 60 months]
